MARKET

VXRT

VXRT

Vaxart Inc
NASDAQ
1.290
+0.070
+5.74%
After Hours: 1.320 +0.03 +2.32% 19:49 03/27 EDT
OPEN
1.220
PREV CLOSE
1.220
HIGH
1.310
LOW
1.210
VOLUME
1.64M
TURNOVER
0
52 WEEK HIGH
1.590
52 WEEK LOW
0.5300
MARKET CAP
224.28M
P/E (TTM)
-2.2655
1D
5D
1M
3M
1Y
5Y
Weekly Report: what happened at VXRT last week (0318-0322)?
Weekly Report · 2d ago
Press Release: Vaxart, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Vaxart, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) to the Company's new President and Chief Executive Officer, Steven Lo, effective March 18, 2024. Vaxart is a clinical-stage biotechnology company developing a range of oral recombinant vaccines.
Dow Jones · 03/20 12:00
Buy Rating Affirmed for Vaxart Amid Promising Vaccine Trials and Strategic Advancements
Mayank Mamtani from B.Riley Financial reiterated a Buy rating on Vaxart (VXRT) with a price target of $2.00. The company's lead norovirus vaccine candidate is nearing the end of Phase II trials with promising immunogenicity and efficacy data.
TipRanks · 03/20 11:25
Weekly Report: what happened at VXRT last week (0311-0315)?
Weekly Report · 03/18 10:05
VXRT Stock Earnings: Vaxart Beats EPS, Beats Revenue for Q4 2023
Vaxart reported earnings per share of -12 cents for the fourth quarter of 2023. The company reported revenue of $3.25 million. This was 159.60% better than the analyst estimate for revenue. Vaxart also reported results for the third quarter of 2018.
Investorplace · 03/15 00:55
Vaxart GAAP EPS of -$0.57 beats by $0.02, revenue of $7.4M beats by $2.19M
Earnings News Vaxart GAAP EPS of -$0.57 beats by $0.02, revenue of $7.4M beats by $2.19M. Cash, cash equivalents and investments totaled $39.7 million as of December 31, 2023.
Seeking Alpha · 03/14 20:15
Options Volatility and Implied Earnings Moves Today, March 14, 2024
Several major companies are expected to report earnings today. Adobe (ADBE), Dollar General (DG) and Weibo (WB) are among the companies. TipRanks shows you the expected earnings move, based on options prices. The list is divided by the timing of each company's earnings release.
TipRanks · 03/14 12:05
Earnings Scheduled For March 14, 2024
Pharming is projected to report earnings for its fourth quarter. Dick's Sporting Goods is expected to report quarterly earnings at $3.35 per share on revenue of $817.48 million. Other companies expected to release earnings before the bell include Hello Gr, Weibo and Build-A-Bear Workshop.
Benzinga · 03/14 09:52
More
About VXRT
Vaxart, Inc. is a clinical-stage biotechnology company that is primarily focused on the development of oral recombinant vaccines based on its Vector-Adjuvant-Antigen Standardized Technology (VAAST) proprietary oral vaccine platform. Its vaccines are designed to be administered using pills that can be stored and shipped without refrigeration and eliminate the risk of needle-stick injury. Its development programs include pill vaccines designed to protect against norovirus (cause for acute gastroenteritis), coronavirus, including SARS-CoV-2 (COVID-19)), and influenza. In addition, it has generated preclinical data for its therapeutic vaccine candidate targeting cervical cancer and dysplasia caused by human papillomavirus. The Company's platform technology employs a vector-based approach and consists of various components, such as a vector (adenovirus type 5 (Ad5); an antigen (Ad5 DNA); an adjuvant (Toll-like receptor 3 (TLR3)), and its proprietary enteric-coated tablet.

Webull offers Vaxart Inc stock information, including NASDAQ: VXRT real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, VXRT stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading VXRT stock methods without spending real money on the virtual paper trading platform.